With strong off-label use already, even with new warnings about the risk of developing second primary malignancies, the new approval for Celgene Corp.’s oral immunomodulator Revlimid (lenalidomide) in newly diagnosed multiple myeloma – with continuous use to disease progression – should continue growth for the company’s pivotal product.
The new indication, cleared Feb. 18, satisfies a long-standing goal for the company. Revlimid was first approved in 2006 for...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?